Oxylanthanum Carbonate (OLC) — PDUFA
Mar 25
The FDA has deemed the OLC resubmission a Class II with a six-month review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027.Source filing